Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 156

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 156
---
, whether due or to become due, and whether or not required to be accrued on the financial statements of such Person; and (ii) any Requisite Regulatory Approvals;

8.9.34 “ Lien” means, with respect to any asset (including any security), any mortgage, lien, pledge, charge, claim, security interest or encumbrance of any kind in respect of such asset or any agreement so to encumber such asset;

8.9.35 “ Lookback Date” means the date of incorporation of the relevant Persont;

| 42 |

8.9.36 “ Material Adverse Effect” means on or with respect to (x)the Company, or (y)SKNY, as the case may be, any state of facts, change, development, effect, condition or occurrence which, individually or in the aggregate, has or would reasonably be expected to have, a materially adverse impact on:

(a) the business, assets, Liabilities, condition (financial or otherwise), financial position or results of operations of such Person, taken as a whole, providedthat “Material Adverse Effect” for purposes of this sub-Section ( a) shall be deemed to exclude the impact of (a)changes in Applicable Laws (or interpretations thereof) of general applicability or interpretations thereof by Governmental Entities, (b)changes or modifications in GAAP, (c)actions and omissions of the Company taken with the prior consent of SKNY (in the case of the Company) or SKNY (in the case of the Company), (d)general national or international economic, financial, political or business conditions, (e)acts of terrorism or war (whether or not declared), (f)changes to the industries in which such Person s, as the case may be, operates in general and not specifically relating to such Person, (g)the announcement of this Agreement or the Merger, including, without limitation, any stockholder litigation related to this Agreement, (h)changes in the price or trading volume of the Company Common Stock, as the case may be (it being understood that any cause underlying such change may be taken into consideration when determining whether a Material Adverse Effect has occurred unless such cause is otherwise excluded), or (i)any failure by such Person to meet internal projections or forecasts or third-party revenue or earnings predictions for any period (it being understood that any cause of any such failure may be taken into consideration when determining whether a Material Adverse Effect has occurred, unless